Back to Browse Journals » Vascular Health and Risk Management » Volume 5

Vascular calcifications as a marker of increased cardiovascular risk: A meta-analysis

Authors R J M W Rennenberg, A G H Kessels, L J Schurgers, J M A van Engelshoven, P W de Leeuw, A A Kroon

Published 22 January 2009 Volume 2009:5 Pages 185—197

DOI https://doi.org/10.2147/VHRM.S4822

Review by Single-blind

Peer reviewer comments 2

R J M W Rennenberg1, A G H Kessels2, L J Schurgers3, J M A van Engelshoven4, P W de Leeuw1, A A Kroon1

1Department of Internal Medicine; 2Department of Clinical Epidemiology and Medical Technology Assessment; 3Department of Biochemistry (VitaK); 4Department of Radiology, University Hospital Maastricht and Cardiovascular Research Institute Maastricht (CARIM), The Netherlands

Background: Several imaging techniques may reveal calcification of the arterial wall or cardiac valves. Many studies indicate that the risk for cardiovascular disease is increased when calcification is present. Recent meta-analyses on coronary calcification and cardiovascular risk may be confounded by indication. Therefore, this meta-analysis was performed with extensive subgroup analysis to assess the overall cardiovascular risk of finding calcification in any arterial wall or cardiac valve when using different imaging techniques.

Methods and results: A meta-analysis of prospective studies reporting calcifications and cardiovascular end-points was performed. Thirty articles were selected. The overall odds ratios (95% confidence interval [CI]) for calcifications versus no calcifications in 218,080 subjects after a mean follow-up of 10.1 years amounted to 4.62 (CI 2.24 to 9.53) for all cause mortality, 3.94 (CI 2.39 to 6.50) for cardiovascular mortality, 3.74 (CI 2.56 to 5.45) for coronary events, 2.21 (CI 1.81 to 2.69) for stroke, and 3.41 (CI 2.71 to 4.30) for any cardiovascular event. Heterogeneity was largely explained by length of follow up and sort of imaging technique. Subgroup analysis of patients with end stage renal disease revealed a much higher odds ratio for any event of 6.22 (CI 2.73 to 14.14).

Conclusion: The presence of calcification in any arterial wall is associated with a 3–4-fold higher risk for mortality and cardiovascular events. Interpretation of the pooled estimates has to be done with caution because of heterogeneity across studies.

Keywords: calcification, cardiovascular risk, meta-analysis, imaging

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Eickels MV, Turpie AGG

Vascular Health and Risk Management 2014, 10:425-434

Published Date: 17 July 2014

Role of nanostructured gold surfaces on monocyte activation and Staphylococcus epidermidis biofilm formation

Svensson S, Forsberg M, Hulander M, Vazirisani F, Palmquist A, Lausmaa J, Thomsen P, Trobos M

International Journal of Nanomedicine 2014, 9:775-794

Published Date: 7 February 2014

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib

C Lance Cowey, Guru Sonpavde, Thomas E Hutson

OncoTargets and Therapy 2010, 3:147-155

Published Date: 20 September 2010

Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials

Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli, Paolo Verdecchia

Vascular Health and Risk Management 2009, 5:411-427

Published Date: 8 May 2009

Fludarabine in the treatment of chronic lymphocytic leukemia: a review

Francesca Ricci, Alessandra Tedeschi, Enrica Morra, Marco Montillo

Therapeutics and Clinical Risk Management 2009, 5:187-207

Published Date: 4 March 2009

Risk factors associated with methamphetamine use and heart failure among Native Hawaiians and other Pacific Island peoples

Marjorie K Mau, Karynna Asao, Jimmy Efird, Erin Saito, Robert Ratner, et al

Vascular Health and Risk Management 2009, 5:45-52

Published Date: 7 December 2008

Drug-eluting stents in the management of peripheral arterial disease

Marc Bosiers, Catherine Cagiannos, Koen Deloose, Jürgen Verbist, Patrick Peeters

Vascular Health and Risk Management 2008, 4:553-559

Published Date: 6 June 2008

Higher persistence with valsartan compared with enalapril in daily practice

Satu J Siiskonen, Nancy S Breekveldt-Postma, Gábor Vincze, Zeba M Khan, Joëlle A Erkens, et al

Vascular Health and Risk Management 2007, 3:1039-1044

Published Date: 15 January 2008